Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) Regimen

Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) Regimen

<b>Background:</b> Studying single-nucleotide polymorphisms (SNPs) in xenobiotic-transporting and metabolizing enzyme genes before administering the doxorubicin hydrochloride and cyclophosphamide (AC) regimen may help optimize breast cancer (BC) treatment for individual patients. <b&g...

Full description

Saved in:
Bibliographic Details
Main Authors: Esraa K. Abdelfattah, Sanaa M. Hosny, Amira B. Kassem, Hebatallah Ahmed Mohamed Moustafa, Amany M. Tawfeik, Marwa N. Abdelhafez, Wael El-Sheshtawy, Bshra A. Alsfouk, Asmaa Saleh, Hoda A. Salem
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Pharmaceuticals
Subjects:
single-nucleotide polymorphism
SNP
AC regimen
rs2228100
rs12248560
rs1045642
Online Access:https://www.mdpi.com/1424-8247/18/4/539
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1424-8247/18/4/539

Similar Items